Distinct Postsurgical Management in Young and Elderly Breast Cancer Patients Results in Equal Survival Rates

Oran, Ebru; Yankol, Yücel; Soybir, Gürsel; Karsidag, Tamer; Sakalli, Onur; Geçgel, Ümit; Soybir, Onur Can; Soran, Atilla

doi:10.7314/apjcp.2014.15.18.7843

Cited by 8 publications

(7 citation statements)

References 44 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer is one of the most common types of malignant tumor and is a serious threat to the health of the patient (12). A previous study found that there was no expression of P2X7R in normal breast tissues; however, P2X7R was overexpressed in breast cancer tissue (13).…”

Section: Discussionmentioning

confidence: 99%

Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells

Tan

Han

Zou

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to investigate the effects of P2X7R short hairpin (sh)RNA on the proliferation and apoptosis of MCF-7 cells, and to detect the expression of P2X7R in breast cancer and MCF-7 cells. In order to detect the expression of P2X7R in normal breast and breast cancer tissues, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), western blot analysis and immunohistochemistry were performed. A P2X7-targeted shRNA sequence and a scrambled sequence were inserted into the pLKO.1 expression vector, and MCF-7 cells with stable transfection of P2X7R-shRNA and P2X7R-scrambled shRNA (control) were selected. qRT-PCR was used to detect the mRNA expression levels of P2X7R in the MCF-7 cells transfected with P2X7R-shRNA and scrambled shRNA. In addition, protein expression levels of P2X7R in the fresh tumor tissues were detected by western blot analysis. An MTT assay was used to detect the proliferation rate at different time points, while flow cytometry was used to detect the growth inhibition and apoptosis rate of the stably transfected MCF-7 cells. P2X7R expression levels in the breast cancer tissues were higher when compared with the normal breast tissue, and a positive correlation was observed with the estrogen receptor (ER), as shown by qRT-PCR, western blot analysis and immunohistochemistry. Plasmids expressing P2X7 gene-specific shRNA and scrambled shRNA were constructed and transfected into MCF-7 cells. The qRT-PCR results revealed lower mRNA expression levels of P2X7 in the P2X7R-shRNA cells when compared with the scrambled shRNA cells. Furthermore, western blot analysis demonstrated that P2X7 protein was highly expressed in the MCF-7 cells transfected with scrambled shRNA, while low expression was observed in the P2X7R-shRNA-transfected cells. Following transfection of the recombinant plasmids into the MCF-7 cells, the proliferation rate in each group was analyzed. The P2X7R-shRNA and KN-62 groups were shown to have significantly reduced rates of proliferation when compared with the normal control group. In addition, flow cytometry revealed that the P2X7R-shRNA and KN-62 groups exhibited a reduced level of cell proliferation and a higher rate of apoptosis. In conclusion, P2X7R was shown to be overexpressed in breast cancer tissues and positively associated with ER expression. A P2X7R-shRNA expression vector effectively inhibited P2X7R expression in MCF-7 breast cancer cells, which subsequently induced cell apoptosis and reduced the levels of cell proliferation. These results indicated that P2X7R may serve as a potential target for breast cancer treatment and prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells

Tan

Han

Zou

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Grade, Ki-67, and molecular subtypes are important prognostic factors for breast cancer (21). Young patients with breast cancer have been reported to have a higher proliferation rate,more grade 3 tumors, and worse molecular subtypes (3,22,23). Breast cancer has different biological properties that vary from person to person.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that younger patients are diagnosed at more advanced stages due to lack of screening mammography, dense breast parenchymal structure, and low awareness of patients (19,23,25). Reviews indicating that younger patients present with advanced staged breast cancer have also been published (26).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Emiroğlu¹,

Karaalı²,

Sert³

et al. 2015

J Breasth Health

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate the clinical, pathologic and management differences between breast cancer patients under 35 years of age and postmenopausal patients above 55 years of age. Materials and Methods:Patients who were operated on for breast cancer between November 2003 and March 2013 in our hospital were retrospectively analyzed. Patients were separated into two Groups according their age; Group 1 (<35 years) and Group 2 (>55 years).Results: 94 patients with breast cancer, 45 patients in Group 1 and 49 patients in Group 2, were included in the study. The mean follow-up was 51 (19-121) months and 50 (19-120) months in Groups 1 and 2, respectively. Stages of breast cancer at the time of diagnosis were similar between the two groups. The groups were similar in terms of rates of re-excision (p=0.42), local recurrence (p=0.34) and solid organ metastases (p=0.182). The number of oncoplastic and reconstructive procedures were higher in Group 1 (p=0.04). Regarding pathological results, the rate of grade 3 tumors, those with Ki-67>12 and triple negative breast cancer were found to be higher in Group 1. In addition, the number of patients receiving chemotherapy was significantly higher in Group 1 (p=0.03). Conclusion:Oncologic results were similar between young patients and postmenopausal patients. Nevertheless, tumor biology was found to be worse in young patients. In addition, oncoplastic and reconstructive approaches were significantly higher in young patients.

show abstract

“…Histolojik grade, Ki-67 ve moleküler alt tipler meme kanserinde önemli prognostik faktörlerdendir (20) . Genç yaştaki meme kanserli hastaların daha yük-sek proliferasyon oranına ve daha kötü moleküler alt tiplerine sahip oldukları bildirilmiştir (7,21) . Göksu ve ark.…”

Section: Discussionunclassified

“…Yaş gruplarına bakılmaksızın semptomatik olarak ilk baş-vuru sonucunda saptanan meme kanseri tanısında daha ileri evreler görülebilmektedir. Genç yaştaki grupta meme kanserinin tarama mamografisinin yapı-lamaması, hızlı metabolizma nedeniyle tümörün hızlı büyüdüğü görüşü, memenin yoğun parankimal yapı-sı, hasta farkındalığının düşük olmasından dolayı daha ileri evrelerde tanı konulduğu bildirilmiştir (7,17,21) . Çalışmamıza göre tanı sırasında meme kanserinin evresi hastanın yaşına göre değişmemektedir.…”

Section: Discussionunclassified

Evaluation of patients with breast cancer 40 years of age and under and 70 years of age and older

Üreyen¹,

İlhan²,

Dadalı³

et al. 2016

Terh

View full text Add to dashboard Cite

ÖZAmaç: Çalışmadaki amacımız kırk yaş ve altı ile yetmiş yaş ve üstü meme kanserli hastaların klinik ve histopatolojik özellikler ile tedavi yaklaşımlarını karşılaştırmak ve prognostik faktörler açısından yaşa göre farklılık olup olmadığını incelemektir. Yöntem: Kliniğimizde invaziv meme karsinomu nedeniyle ameliyat edilen 40 yaş ve altı (Grup I) ile 70 yaş ve üstü (Grup II) hastalar retrospektif olarak tümör histopatoloji tipi, uygulanan cerrahi, aksiler tutulum ve prognostik parametreler yönünden irdelendi. Bulgular: Grup I'de 15 (%55,6), Grup II'de 12 (%44,6) meme kanserli hasta çalışma-ya dâhil edildi. Grup I'de 7 (%46) ve Grup II'de 2 (%16)) hastaya meme koruyucu cerrahi (MKC) uygulandı. Operasyon tipinin grup içi karşılaştırılmasında Grup II olgularının ameliyat tipinde anlamlı farklı bulundu (p=0,021). Gruplar arasında histopatoloji sonucu açısından anlamlı fark bulunmamış (p>0,05) olup, grup içi karşılaş-tırılmasında Grup I hastalarının histopatoloji sonucunda anlamlı farklı bulundu (p=0,001). Erken ve lokal ileri evre açısından Grup I ve Grup II arasında sırasıyla %66,7'ye karşın %33,3 oranında erken evreye rastlandı. Gruplar içi karşılaştırmada Grup II olgularının, ER pozitifliği, PR pozitifliği ve moleküler altgrup sınıflaması dağılımları beklenen dağılımlardan anlamlı farklı bulundu (p<0,05). Sonuç: Genç yaş ve ileri yaş meme kanserlerinde benzer prognostik faktörlerin varlı-ğının yanı sıra her bir grup kendine özgün iyi ya da kötü prognostik faktörlere sahip olabilir.Anahtar kelimeler: Meme kanseri, genç yaş, ileri yaş, prognostif faktör ABSTRACT Objective: The aim of our study is to compare clinicopathological features; and treatment approaches, and investigate if any age-related difference exists in prognostic factors between breast cancer patients aged ≤ 40, and ≥ 70 years. Methods: Patients aged ≤ 40 (Group 1) and ≥ 70 years (Group 2) who had surgical intervention for invasive breast carcinoma were evaluated retrospectively in terms of histological type, surgical procedure, axillary involvement and prognostic parameters. Results: Fifteen (55.6%) patients in Group 1 and 12 (44.6%) in Group 2 were included in the study Breast-conserving surgery was performed for 7 (46%) patients in Group 1 and 2 (16%) patients in Group 2. In intergroup comparison of groups, a statistically significant difference was found in Group 2 in terms of operation type (p=0.021).There were no significant difference between groups in terms of histopathological results (p>0.05), however, intragroup comparisons of the results in Group 1 yielded significant differences (p=0.001). Early, and locally advanced disease stages were detected in 66,7% of Group 1 and 33,3% of Group 2 patients. There were significant intragroup differences in Group 2 patients, in terms of ER, and PR positivity and molecular subtypes (p<0.05). Conclusion: Younger, and advanced age patients with breast cancer may have similar prognostic factors, while each group may have unique prognostic parametres.

show abstract

Distinct Postsurgical Management in Young and Elderly Breast Cancer Patients Results in Equal Survival Rates

Cited by 8 publications

References 44 publications

Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells

Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Evaluation of patients with breast cancer 40 years of age and under and 70 years of age and older

Contact Info

Product

Resources

About